GHO capital launches EU’s largest fund ever for life sciences

Global Healthcare Opportunities, or GHO Capital Partners LLP said that its finally closed Fund II will be focussed on high growth healthcare subsectors, including outsourced services, pharma and medtech. With €960m, Fund II was oversubscribed compared to the initial target size of €800m and approximately 50% larger than the firm’s Fund I raised in 2015. With over €2bn raised in total, GHO Capital Partners represents Europe’s largest fundraiser.

The Fund is aimed at develoing the untapped market opportunities in pharma, medtech and outsourced services, through growth buyout investments. With a pan-European focus, the Fund also has the capability to draw upon GHO’s extensive international network to capture and accelerate transatlantic growth opportunities. Within the last six months, GHO exited investments in Caprion Biosciences and Quotient Sciences, having successfully leveraged organic and inorganic growth opportunities to create transatlantic sector leaders.

According to the partners, the significant size of the Fund reflects the increasing maturity of the European healthcare sector and the level of investor interest and support for developing healthcare businesses that address global issues and trends.

Fund II has already made two investments in Q1/2019, investing alongside management in Sterling Pharma Solutions, a leading provider of small molecule API development and manufacturing services to the global pharmaceutical industry, as well as in BioAgilytix, an independent global provider of large molecule bioanalytical testing solutions. GHO Capital is advised by placement agent Rede Partners and law firm Debevoise & Plimpton LLP.